The updated forecast for Moderna (MRNA) is here
What’s up with Moderna?
Moderna (MRNA) opened at $50.48, which means the stock is down 3.80% from yesterday’s closing price of 50.50. Today, the company has a high of $50.96 and a low of $47.23. The company has a market cap of $16.23 billion with a 52-week high of $56.38 and a 52-week low of $11.54.
What about the future for Moderna?
The high forecast for Moderna is 83.00 while the low is 32.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Moderna has a weak forecast. A weak forecast is due to the company posting consistent losses in their earning reports. The future outlook does not seem too bright as this could potentially cause the company to file for bankruptcy.. Based on this information MRNA seems to be a risky buy.
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.